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ExPloRing thE UsE of ValUE of infoRMation MEthods to PRioRitisE 
REsEaRch to addREss thE tREatMEnt UncERtaintiEs idEntifiEd By thE 
JaMEs lind alliancE PRioRity sEtting PaRtnERshiPs
Sach T, McManus E
University of East Anglia, Norwich, UK
Economic analysis is regularly used to inform decisions on allocating healthcare 
budgets but not routinely for allocating health research budgets which may mean 
that the research budget is not delivering value for money. The study aims to use 
‘value of information’ analysis to prioritise research funding across an entire clini-
cal area. In particular, exploring the usefulness of such methods in prioritising the 
treatment uncertainties identified by the James Lind Alliance (JLA) Priority Setting 
Partnership (PSP) for atopic eczema. Whilst the research will primarily identify what 
the future research priorities within eczema should be, it will also act as a case study 
of how such methods could be applied to JLA PSPs for other conditions. The poten-
tial benefit of this research is in reducing the first two stages of research waste (i) 
‘Questions relevant to research users?’ And (ii) ‘Appropriate research design, conduct 
and analysis?’ identified by Chalmers and Glasziou (2009). The methods proposed 
for doing the work will be described, with a focus on those stages already underway. 
This includes defining the decision problems, building on the work of the eczema 
JLA PSP, and conceptual modelling, understanding the disease process and service 
pathways for eczema with expert input. The potential usefulness and challenges of 
the approach will be discussed. Strengthening methods around research prioritisa-
tion and study design is important to ensure value for money from limited research 
funding. Reference: Chalmers I, Glasziou P. Avoidable waste in the production and 
reporting of research evidence. Lancet 2009; 374: 86-89
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UsE of a MUlti-dEcision cRitERia analysis to sUPPoRt hEalthcaRE 
dEcision-Making foR PRiVatE PayERs in BRazil: dEVEloPMEnt of a 
ModEl to gUidE REiMBURsEMEnt dEcisions
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Objectives: Although the use of cost-effectiveness analysis has been increasing in 
Brazil, there is no evidence of an appropriate willingness-to-pay value to interpret 
results. The objective of this study is to develop an alternative model to support 
reimbursement decisions of private payers in Brazil. MethOds: A value meas-
urement Multi Decision Criteria Analysis (MCDA) model was developed in order 
to reflect different dimensions that influence healthcare decisions. A literature 
review was performed in order to identify the most common criteria and scores 
scales to be included in the model, which was further complemented by expert 
opinion. Analytical hierarchy process was used to weight the importance of each 
dimension by pairwise comparisons. A group representing different stakeholders 
(academia, payer, industry, health service provider and physician) was formed in 
order to consider different perspectives when validating the final model. Results: 
A simple linear additive model with four dimensions (clinical impact, strength of the 
evidence, economic impact and feasibility of adoption) was developed based on the 
literature. After validation by expert opinion, these 4 dimensions were divided into 
a total of 10 criteria (“treatment costs”, “indication prevalence”, “level of evidence”, 
“relevance of outcome”, “impact on health”, “severity of disease”, “feasibility of 
adoption”, “legal implications”, “ethical implications” and “technology position-
ing”). Weights for each criterion were assigned, with disproportional values given to 
“legal implications” and “ethical implications”, as these were considered mandatory 
requirements. The final score was then classified into 5 options based on the likeli-
hood of recommendation. Univariate sensitivity analysis to the assigned weights 
was performed to check the robustness of the results. cOnclusiOns: The proposed 
MCDA model may provide additional support to prioritize and guide reimbursement 
decisions for individual payers in the private Health System in Brazil.
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Objectives: A preliminary model was built early in the development pathway for a 
new vaccine. The vaccine had been studied in phase II trials but was yet to be tested 
in a phase III study. The twin objectives of the model was to determine the highest 
price for the vaccine where it remains cost effective and to identify which variables 
will most determine cost effectiveness. MethOds: A simple decision analytic model 
was built to determine the cost per QALY associated with the use of the vaccine 
in an elderly population. A literature search was undertaken to identify published 
evidence to populate the model. The model was run for a cohort equal to the total 
population in the countries for which the model was developed. This enabled the total 
budget requirement for a national vaccination program to be estimated. Results: 
The model generated a price up to $600 per course of vaccine and with a cost per 
QALY of $US50,000. The main drivers of the cost effectiveness was the frequency; cost 
per episode of care for hospital addmissions, the incremental efficacy of the vaccine 
and mortally associated with the underlying infection. cOnclusiOns: The model 
identified a number of areas which would be important for data collection, these are 
mostly related. It shows the value of early decision analytic modelling to determine 
the threshold price and the data gaps. This will help the organisation developing the 
vaccine to focus research on collecting information which will be useful when applica-
tions are being made for reimbursement of the vaccine in the future.
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can adVancEs in hEalth MonitoRs lEad to hEalth BEing lookEd at as 
a coMModity?
Focsa S
Executive Insight, Zug, SC, Switzerland
As advances in health monitors are being developed the opportunity for them to be 
integrated into daily healthcare infrastructure is also expanding. Many healthcare 
systems are facing increasing budgetary pressure and are finding it hard to make 
decisions about what treatments to cover. The willingness to pay a fair price for 
the benefits of healthcare is present; however, the current infrastructure and 
evaluation process has limitations. Patients can gain different benefits from the 
same treatments while also incurring the same cost. Drug evaluations are lengthy 
and complex processes, especially for ones that have multiple indications, sub-
populations and formulations to consider. Market restrictions of having one price 
per brand often leads to access restrictions not allowing patients to benefit fully 
from the treatments available. Furthermore, costs for non-compliant patients 
and adverse events are also upheld by current healthcare systems meaning that 
the cost per benefits are not fully realized. Continuous monitoring of patients 
could pave the way forward for scalable, accurate and effective payment by result 
systems that will allow patient benefits to be directly linked to the cost of treat-
ment. If monitors can accurately evaluate the amount of benefit each patient 
gains from treatment it can effectively remove the need for drug pricing as a 
whole, only a cost per unit of health would need to be established and healthcare 
systems would pay for the total benefits gained by the population, similar to how 
electricity is paid for using a meter. This change could allow drugs to enter markets 
with fewer restrictions and be used optimally by physicians where they feel they 
add the most benefit to patients. Furthermore, patient compliance and adverse 
events would become the financial responsibility of the drug provider, they will 
need to enforce monitoring, compliance and incentivize on-label use to provide 
the maximum patient benefits.
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coRRElation in stochastic dEcision ModEls
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Objective: To present a method for evaluating uncertainty due to unknown 
parameter correlations in stochastic decision models. MethOds: The use of 
probabilistic sensitivity analysis (PSA) has grown significantly in health economic 
decision modeling. When parameter correlations are known various methods exist 
to evaluate uncertainty in PSAs to account for correlations (eg, Cholesky decom-
position). However, in cohort analyses, using literature-based data, parameter cor-
relations are seldom known and it is therefore typically assumed that parameters 
are uncorrelated and independent. We present a method and worked example to 
explore uncertainty due to parameter correlation in the absence of known correla-
tions. For a decision model with n parameters a n x n diagonal correlation matrix 
defining all parameter correlations is developed. With the SIMTOOLS add-in, the 
CORAND function and correlation matrix are used to generate correlated random 
numbers for the model simulation. For the base case all parameters in the matrix 
are assumed to be independent and the correlations are set to zero. Systematic 
analyses can then be conducted in which model parameters, individually or in 
groups, are correlated to explore the potential impact of parameter correlation 
on the model outcomes. We report the results of a sample analysis and show 
that parameter correlations can have a significant impact on model uncertainty. 
While the median ICERs did not change significantly, the 95% confidence intervals 
ranged widely as the shape of the ICER-scatterplots changed. Parameters with 
little impact in deterministic sensitivity analyses were observed to contribute to 
significant uncertainty in the correlation analysis. cOnclusiOns: In stochas-
tic decision models where parameter correlations are unknown, it is possible 
to evaluate uncertainty due to potential parameter correlations in Excel-based 
decision models. Unknown parameter correlations may be a significant source of 
uncertainty. Future research is needed to validate this method in comparison to 
methods for evaluating known parameter correlations.
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foR tREatMEnt switching
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Treatment switching occurs in a clinical trial when control arm patients switch to 
experimental therapy during the study. This often happens in oncology trials where 
patients switch following disease progression, and can reduce the observed survival 
difference. An estimate of the survival effect without switching may be required for 
economic modelling, and several methods have been developed to estimate this. 
In 2014, the NICE Decision Support Unit published Technical Support Document 
(TSD) 16 to provide guidance on this. There are several practical considerations for 
the statistician or analyst wanting to apply these methods to clinical trials data. 
The analysis framework proposed in TSD16 is useful, but it can be difficult to apply 
retrospectively unless the trial was designed with this objective in mind. So are there 
any trial design features that should be included in the protocol at the start? The 
right data must be collected to enable the methods to be applied – what data is that, 
is it practical to collect it all, what should be done if not? Each method has strong 
underlying assumptions such as a constant treatment effect or no unmeasured 
confounders – how could those assumptions be assessed for viability? Several recent 
health technology assessments have tried to apply these methods and shown either 
very different results from different models, or have struggled to fit the models at 
all. Why might that be? What could the analyst do in this situation? Guidance will be 
provided on these issues based on experience of applying these methods to real-life 
data and a review of recent health technology assessments.
